Since then, EGFR TKIs, such as gefitinib and the equally effective erlotinib, have become the first-line treatment option for NSCLC patients in which the tumor harbors activating EGFR mutations, based on the results of a number of phase III trials (4–9). Here, EGFR is linked to neoplasm.